What the FDA labels say about taking them together
Aripiprazole and fluoxetine
Aripiprazole's FDA label of January 29, 2025 names fluoxetine in its drug interactions section; fluoxetine's label does not name aripiprazole itself but warns about its class (Atypical antipsychotics). The aripiprazole label: “Reduce the ABILIFY dosage when administered concomitantly with a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor.”
Check it at the source: the aripiprazole FDA label on DailyMed (effective January 29, 2025, Otsuka America Pharmaceutical, Inc.); the fluoxetine FDA label on DailyMed (effective January 8, 2026, Dista Products Company).
What does the aripiprazole label say about fluoxetine?
Aripiprazole label, drug interactionsConcomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine); Clinical Rationale: Concomitant use of ABILIFY with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of ABILIFY alone [see ].; Clinical Recommendation: Reduce the ABILIFY dosage when administered concomitantly with a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor [see ].
Abilify Maintena label (Otsuka America Pharmaceutical, Inc., March 24, 2026), drug interactionsConcomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine); Clinical Rationale: The concomitant use of oral aripiprazole with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole [see ].; Clinical Recommendation: With concomitant use of ABILIFY MAINTENA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 14 days, reduce the ABILIFY MAINTENA dosage [see ].
Source: FDA drug label (Abilify Maintena, NDA202971), Otsuka America Pharmaceutical, Inc., effective March 24, 2026 (SPL set ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6), via openFDA
Source: FDA drug label (ABILIFY), Otsuka America Pharmaceutical, Inc., effective January 29, 2025 (SPL set c040bd1d-45b7-49f2-93ea-aed7220b30ac), via openFDA; the full label on DailyMed
What does the fluoxetine label say about aripiprazole?
Fluoxetine's label does not name aripiprazole itself; it warns about its class (Atypical antipsychotics):
Fluoxetine label, drug interactionsUse PROZAC with caution in combination with other drugs that cause QT prolongation. These include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin);
Fluoxetine label, warnings and precautionsAvoid the concomitant use of drugs known to prolong the QT interval. These include specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol,); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin);
Source: FDA drug label (Prozac), NDA018936 (Eli Lilly And Co), as published by Dista Products Company, effective January 8, 2026 (SPL set c88f33ed-6dfb-4c5e-bc01-d8e36dd97299), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aripiprazole | Fluoxetine | |
|---|---|---|
| Labeled for | Depression, Bipolar disorder, Schizophrenia | Depression, Anxiety, Bipolar disorder |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.110 per tablet 5 mg tablet | $0.0519 per capsule 40 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once